Your browser doesn't support javascript.
loading
Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus.
Mahajan, Anubha; Sim, Xueling; Ng, Hui Jin; Manning, Alisa; Rivas, Manuel A; Highland, Heather M; Locke, Adam E; Grarup, Niels; Im, Hae Kyung; Cingolani, Pablo; Flannick, Jason; Fontanillas, Pierre; Fuchsberger, Christian; Gaulton, Kyle J; Teslovich, Tanya M; Rayner, N William; Robertson, Neil R; Beer, Nicola L; Rundle, Jana K; Bork-Jensen, Jette; Ladenvall, Claes; Blancher, Christine; Buck, David; Buck, Gemma; Burtt, Noël P; Gabriel, Stacey; Gjesing, Anette P; Groves, Christopher J; Hollensted, Mette; Huyghe, Jeroen R; Jackson, Anne U; Jun, Goo; Justesen, Johanne Marie; Mangino, Massimo; Murphy, Jacquelyn; Neville, Matt; Onofrio, Robert; Small, Kerrin S; Stringham, Heather M; Syvänen, Ann-Christine; Trakalo, Joseph; Abecasis, Goncalo; Bell, Graeme I; Blangero, John; Cox, Nancy J; Duggirala, Ravindranath; Hanis, Craig L; Seielstad, Mark; Wilson, James G; Christensen, Cramer.
Afiliação
  • Mahajan A; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Sim X; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Ng HJ; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Manning A; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America.
  • Rivas MA; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Highland HM; Human Genetics Center, The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
  • Locke AE; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Grarup N; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Im HK; Department of Health Studies, Biostatistics Laboratory, The University of Chicago, Chicago, Illinois, United States of America.
  • Cingolani P; School of Computer Science, McGill University, Montreal, Quebec, Canada; McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada.
  • Flannick J; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America; Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
  • Fontanillas P; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America.
  • Fuchsberger C; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Gaulton KJ; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Teslovich TM; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Rayner NW; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Department of Human Genetics, Wellcome Tr
  • Robertson NR; Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Beer NL; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Rundle JK; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Bork-Jensen J; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Ladenvall C; Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Malmö, Sweden.
  • Blancher C; High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Buck D; High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Buck G; High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Burtt NP; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America.
  • Gabriel S; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America.
  • Gjesing AP; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Groves CJ; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Hollensted M; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Huyghe JR; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Jackson AU; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Jun G; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Justesen JM; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Mangino M; Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom.
  • Murphy J; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America.
  • Neville M; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Onofrio R; Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America.
  • Small KS; Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom.
  • Stringham HM; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Syvänen AC; Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Trakalo J; High Throughput Genomics, Oxford Genomics Centre, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Abecasis G; Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America.
  • Bell GI; Departments of Medicine and Human Genetics, The University of Chicago, Chicago, Illinois, United States of America.
  • Blangero J; Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, United States of America.
  • Cox NJ; Department of Medicine, Section of Genetic Medicine, The University of Chicago, Chicago, Illinois, United States of America.
  • Duggirala R; Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas, United States of America.
  • Hanis CL; Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
  • Seielstad M; Blood Systems Research Institute, San Francisco, California, United States of America; Department of Laboratory Medicine & Institute for Human Genetics, University of California, San Francisco, San Francisco, California, United States of America.
  • Wilson JG; Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi, United States of America.
  • Christensen C; Department of Internal Medicine and Endocrinology, Vejle Hospital, Vejle, Denmark.
PLoS Genet ; 11(1): e1004876, 2015 Jan.
Article em En | MEDLINE | ID: mdl-25625282
ABSTRACT
Genome wide association studies (GWAS) for fasting glucose (FG) and insulin (FI) have identified common variant signals which explain 4.8% and 1.2% of trait variance, respectively. It is hypothesized that low-frequency and rare variants could contribute substantially to unexplained genetic variance. To test this, we analyzed exome-array data from up to 33,231 non-diabetic individuals of European ancestry. We found exome-wide significant (P<5×10-7) evidence for two loci not previously highlighted by common variant GWAS GLP1R (p.Ala316Thr, minor allele frequency (MAF)=1.5%) influencing FG levels, and URB2 (p.Glu594Val, MAF = 0.1%) influencing FI levels. Coding variant associations can highlight potential effector genes at (non-coding) GWAS signals. At the G6PC2/ABCB11 locus, we identified multiple coding variants in G6PC2 (p.Val219Leu, p.His177Tyr, and p.Tyr207Ser) influencing FG levels, conditionally independent of each other and the non-coding GWAS signal. In vitro assays demonstrate that these associated coding alleles result in reduced protein abundance via proteasomal degradation, establishing G6PC2 as an effector gene at this locus. Reconciliation of single-variant associations and functional effects was only possible when haplotype phase was considered. In contrast to earlier reports suggesting that, paradoxically, glucose-raising alleles at this locus are protective against type 2 diabetes (T2D), the p.Val219Leu G6PC2 variant displayed a modest but directionally consistent association with T2D risk. Coding variant associations for glycemic traits in GWAS signals highlight PCSK1, RREB1, and ZHX3 as likely effector transcripts. These coding variant association signals do not have a major impact on the trait variance explained, but they do provide valuable biological insights.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Glucose-6-Fosfatase / Diabetes Mellitus Tipo 2 / Insulina Tipo de estudo: Diagnostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: PLoS Genet Assunto da revista: GENETICA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glicemia / Glucose-6-Fosfatase / Diabetes Mellitus Tipo 2 / Insulina Tipo de estudo: Diagnostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: PLoS Genet Assunto da revista: GENETICA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido